Forma Therapeutics has been granted a patent for USP30 Inhibitor Compounds, allowing for the development of pharmaceutical compositions to inhibit USP30 in patients. The method involves administering a compound of Formula I to treat medical conditions. GlobalData’s report on Forma Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Forma Therapeutics Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Forma Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Forma Therapeutics's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11814386B2) discloses a method for inhibiting USP30 in patients in need by administering a compound of Formula I. The method involves the administration of specific compounds, including those of formula (I-C), (I-1), (I-2), (I-3), and (I-4), each with distinct structural characteristics. The compounds are designed to target USP30 effectively, offering a potential therapeutic approach for patients requiring USP30 inhibition.

Furthermore, the patent claims detail specific structural configurations for the compounds, such as the formation of alkylene groups between certain atoms and the presence of hydrogen atoms at designated positions. The method also includes variations in the structure of the compounds, such as the formation of cycloalkyl or heterocycloalkyl groups and the inclusion of specific arylene and phenylene components. By providing a range of compound options and structural variations, the patent aims to offer a comprehensive approach to inhibiting USP30 in patients, potentially opening up new avenues for therapeutic interventions in conditions where USP30 inhibition is beneficial.

To know more about GlobalData’s detailed insights on Forma Therapeutics, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies